Hepatocellular Carcinoma
1,826
296
391
562
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
164 trials with published results (9%)
Research Maturity
562 completed trials (31% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.6%
157 terminated out of 1826 trials
78.2%
-8.3% vs benchmark
11%
206 trials in Phase 3/4
29%
164 of 562 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 562 completed trials
Clinical Trials (1826)
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
Extracellular RNA Markers of Liver Disease and Cancer
Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
LEAF(Liver Tumor dEtection And classiFication AI)
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCC
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
TheraSphere With Durvalumab and Tremelimumab for HCC